Recently, many efforts have been made to exploit strategies to develop novel therapies for NPC, and this has led to the development of epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial growth factor (VEGF) inhibitors and immunotherapeutic drugs1,16. The gene discussed is VEGFA; the disease is nasopharyngeal carcinoma.